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ABSTRACT: Epidemiological and animal studies have suggested that chronic alcohol consumption is a major
risk factor for osteoporosis. Using bone from cycling female rats infused chronically with ethanol (EtOH) in
vivo and osteoblastic cells in vitro, we found thatEtOH signiﬁcantly increased estrogen receptor a (ERa) and
b (ERb) mRNA and ERa protein levels. Treatment with 17b-estradiol (E2) in vivo and in vitro interfered
with these effects of EtOH on bone and osteoblastic cells. ERa agonist propylpyrazoletriol (PPT) and ERb
agonist diarylpropionitrile (DPN) attenuated EtOH-induced ERa and ERb gene overexpression, respec-
tively. Similar to the ER antagonist ICI 182780, EtOH blocked nuclear translocation of ERa-ECFP in the
presence of E2 in UMR-106 osteoblastic cells. EtOH also downregulated ERE-luc reporter activity. On the
other hand, EtOH by itself upregulated some common ERa- and ERb-mediated genes apparently by an
ER-independent pathway. EtOH also transactivated the luciferase activity of the p21 promoter region
independent of additional exogenous ERa, activated p21 and p53, and stimulated senescence-associated
b-galactosidase activity in rat stromal osteoblasts. E2 treatment attenuated these EtOH actions. We conclude
that inhibitory cross-talk between EtOH and E2 in osteoblasts on ERs, p53/p21, and cell senescence provides
a pathophysiologic mechanism underlying bone loss and the protective effects of estrogens in alcohol-
exposed females.
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INTRODUCTION
C
HRONIC ALCOHOL ABUSE has long been recognized as a
major risk factor for development of osteoporosis.
(1–3)
Recent evidence showed binge alcohol exposure can cause
bone loss as well.
(4) Although the exact mechanism by
which ethanol (EtOH) inﬂuences bone physiology is not
clear, it is likely to involve a combination of both direct
and indirect effects on bone cells.
(5) EtOH can diffuse into
osteoblasts, where alcohol dehydrogenase class 1 (ADH1)
is expressed, and be metabolized to acetaldehyde and give
rise to reactive oxygen species (ROS) that can exert bio-
logical effects.
(6) This is considered a direct effect of EtOH.
On the other hand, chronic alcohol abuse has been shown
to have inﬂammatory effects in bone marrow, which is
known to introduce additional factors that are believed
detrimental to the skeleton.
(3,7,8) These factors, which in-
clude interleukin-1b (IL-1), TNFa, and IL-6, are all se-
creted by mononuclear cells.
(9) EtOH increases RANKL
mRNA expression in bone marrow cells, resulting in
stimulation of osteoclastogenesis and bone resorption, and
this effect was mediated through induction of IL-6.
(10)
Alcohol consumption also suppresses plasma estrogens
in cycling females,
(11) suggesting an association between
EtOH and reduced estrogen signaling in bone.
Estrogen receptors a (ERa)a n db (ERb) mediate es-
trogen action in a variety of tissues and cells. Whereas these
receptors have overlapping responsibilities, they also have
distinct roles in different tissue and cell types.
(12) In human
osteoblastswherebothestrogen receptorsare present,genes
regulated by estrogen through ERa and/or ERb show
commonalities, but also signiﬁcant differences.
(13) Chronic
EtOH ingestion in humans and rats induce an increase in
ER expression in liver and breast.
(14,15) EtOH-induced
increases in mammary ER expression may be associated
with an increased risk of breast cancer. However, the sig-
niﬁcance of EtOH-induced overexpression of ER in other
tissues and the consequences for tissue pathology has
not been studied. Bone is also recognized as an estrogen
sensitive organ, and altered ER signaling in bone cells
are known to affect bone quality. Although we have pre-
viously predicted that EtOH might alter ER signaling in
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221bone cells,
(1) published evidence to support this hypothesis
is lacking.
Overexpression of ERs in osteoblasts has been linked to
activation of p53.
(16) p53 is a well-known tumor suppressor
gene that maintains the integrity of the genome by its
ability to regulate various aspects of cell growth and apo-
ptosis.
(17) p53 is also believed to represent a key compo-
nent of a signal transduction pathway that is stimulated by
increased intracellular ROS to trigger apoptosis, and p53
activation also results in ROS generation in the mito-
chondria.
(18–20) Studies analyzing the role of p53 in differ-
ent cell types have shown a tissue-speciﬁc role for p53 in
differentiation of several tissue types.
(21,22) p53 has been
shown to regulate osteoblast differentiation, bone forma-
tion, and osteoblast-dependent osteoclast differentia-
tion.
(23) Activation of p53 in bone tissue has been observed
both in aged animals and in sex steroid–deﬁcient gonad-
ectomized mice.
(24) Activated p53 has been suggested to be
a link to the senescence pathway in bone cells.
(16) More-
over, EtOH has recently been reported to induce p53.
(25,26)
p21 functions as a downstream effector of p53, and previ-
ous studies have implicated p21 involvement in ER sig-
naling.
(27) These ﬁndings suggest that impaired estrogen
signaling in bone cells after EtOH exposure could accel-
erate senescence
In the studies presented in this report, we attempted to
understand the effect of EtOH treatment in vivo and in
vitro on estrogen receptors and ER signaling compared
with classic ER ligands, such as 17b-estradiol (E2) and ICI
in osteoblasts. We also tried to determine whether EtOH
activates p53 and p21 and its promoter and if this led to
accelerated senescence in osteoblasts. We present a new
paradigm whereby EtOH induces bone loss by impairing
ER signaling and the interaction between ER and p21 to
determine the fate of osteoblasts. These data also provide a
further explanation for why endogenous or exogenous es-
trogens antagonize the toxic effects of EtOH on bone.
MATERIALS AND METHODS
Animals
Female Sprague-Dawley rats (250–260 g) were pur-
chased from Charles River Laboratories (Wilmington,
MA, USA). Animals were housed in an Association for
the Assessment and Accreditation of Laboratory Animal
Care–approved animal facility. Animal maintenance and
experimental treatments were conducted in accordance
with the ethical guidelines for animal research established
and approved by the Institutional Animal Care and Use
Committee at University of Arkansas for Medical Science
(Little Rock, AR, USA). Rats were surgically implanted
with an intragastric cannula as described previously,
(28,29)
and rats were fed by total enteral nutrition (TEN). Liquid
diets were formulated to contain the nutrients recom-
mended for rats by the National Research Council. The
TEN animal model has been detailed previously.
(1) Diets
contained 16% protein, 54% carbohydrate, and 25% fat
(corn oil), and EtOH-containing diets were kept isocaloric
to the control diets by substituting EtOH for carbohydrate
calories. The EtOH dose was 12 g/kg/d. Rats (n = 8/group)
were infused 187 kcal/kg
3/4/d for 14 h from 6:00 p.m. to 8:00
a.m. during the dark cycle for 4 wk. Additional groups of
control and EtOH-infused animals were supplemented
with subcutaneous E2 (20 mg/kg/d; Sigma-Aldrich, St
Louis, MO, USA) administered using Alzet osmotic min-
ipumps.
(1) All rats were weighed every other day, and we
found that there are no signiﬁcant differences among all
four groups in body weight in the end of experiment:
control, 278.1 ± 1.8 g; EtOH, 273.8 ± 2.1 g; E2, 278.1 ± 2.3 g;
E2 + EtOH, 280.2 ± 3.7 g.
Cell culture
Control cycling female rat bone marrow cells were har-
vested from femurs according to methods described pre-
viously.
(30) To have stromal osteoblasts for treatment, bone
marrow cells were seeded at a density of 3 3 10
6 cells/well
in six-well cell culture plates in the presence of MEM
(Invitrogen, Carlsbad, CA, USA) with 10% FBS (Hyclone
Laboratories, Logan, UT, USA) and 1 mM of ascorbyl-2-
phosphate (Sigma-Aldrich), 4 mM L-glutamine, and 100
U/ml of each penicillin and streptomycin (Sigma-Aldrich),
conditions known to drive osteoblast differentiation. One
half the cell culture medium was changed every 5 days,
and after 20 days, mature osteoblasts were developed for
treatment. Neonatal rat calvarial osteoblastic cells were
isolated from untreated 4-day-old rat pups by sequential
collagenase digestion using a method described previ-
ously.
(31) Rat calvarial osteoblastic cells and the rat
osteoblast-like cell line UMR-106 (ATCC, Rockville, MD,
USA) were cultured in aMEM supplemented with 10%
FBS. When cells were ready to be treated, culture medium
was saturated with O2 and CO2 in an incubator for 2 h and
plates were sealed during EtOH treatment; these treat-
ment procedures were detailed previously.
(6)
Real-time RT-PCR analysis
Rat tibial bone RNA and osteoblastic cell RNA were
extracted using TRI Reagent (MRC, Cincinnati, OH,
USA) according to the manufacturer’s recommendation
followed by DNase digestion and column clean-up using
QIAGEN minicolumns. Brieﬂy, at the time of death, the
right tibia was taken, and bone marrow cells were ﬂushed
with Eagle’s MEM + Hanks’ salts after cleaning the sur-
rounding connective tissue. Tibial bones were frozen in
liquid nitrogen. Tibial bone was placed in 1000 ml TRI
Reagent and homogenized using a polytron-aggregate
(Kinematica). One hundred microliters of 1-bromo-3-
chloropropane (BCP) was added, and the mixture was
centrifuged for 15 minat speed of 16,000 rpm and48C. Four
hundred ﬁfty microliters supernatant was taken, and an
equal volume of isopropanol was added and centrifuged
for additional 15 min (16,000 rpm, 48C). After washing the
RNA pellet with 75% ethanol, isolated RNA was resus-
pended in RNase-free water. Treated cells from 6-well
plates were washed with twice with PBS, and 1000 ml TRI
Reagent was added into each well. Cells were scraped into
a 1.5-ml Eppendorf tube. RNA preparation was identical
to that of isolation of RNA from bone tissue. Reverse
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thesis kit from Bio-Rad (Hercules, CA, USA). Real-time
RT-PCR was carried out using SYBR Green and an ABI
7000 sequence detection system (Applied Biosystems,
Foster City, CA, USA). Primers for rat ERa and ERb,
PTH-like hormone (PTHLH), bone morphogenetic pro-
tein 6 (BMP6), phosphodiesterase 3B (PDE3B), Bcl-2-
associated transcription factor (BTF), Autotaxin, and
stromal antigen 2 (STAG2) were designed using Primer
Express software 2.0.0 (Applied Biosystems), and all
primer sequences used in this study are listed in Table 1.
Western blotting
Tibia bone tissue proteins and in vitro cellular proteins
were extracted using a cell lysate buffer as described pre-
viously.
(6) Phosphorylation of p53 and total p53 in bone
tissue and in vitro osteoblasts was assessed by Western
immunoblotting using goat polyclonal antibody recogniz-
ing phosphorylated p53 (Santa Cruz Biotechnology) and
rabbit polyclonal antibody recognizing total p53 (Cell
Signaling), followed by incubation with either an anti-goat
or an anti-rabbit antibody conjugated with horseradish
peroxidase (Santa Cruz). The status of p21, ERa, and
GAPDH protein in bone tissue and in vitro osteoblasts
were analyzed by immunoblotting, using rabbit polyclonal
antibodies recognizing p21 and ERa (Santa Cruz) and a
mouse monoclonal antibody recognizing GAPDH (Santa
Cruz), followed by incubation with either an anti-rabbit or
an anti-mouse antibody conjugated with horseradish per-
oxidase (Santa Cruz) and SuperSignal West Pico chemi-
luminescent substrate (Pierce). Quantitation of the inten-
sity of the bands in the autoradiograms was performed
using a VersaDoc imaging system (Bio-Rad).
DNA constructs and luciferase activity assays
ERa transcriptional activity was determined by mea-
suring the EtOH- and estradiol-stimulated, ERa-mediated
activation of the estrogen-responsive reporter plasmidERE-
TK-Luc. The ERE-TK-Luc reporter and wildtype ERa
plasmid used in this report were published previously.
(32)
Human p21 promoter pGL2-p21-Luc, containing the p21
promoter-luciferase reporter fusion and two p53-binding
consensus sites, was kindly provided by Dr Lieberman.
(33)
ERE-TK-Luc and pGL2-p21-Luc plasmids were trans-
fected into UMR-106 cells with or without ERa co-trans-
fection using Lipofectamine 2000 (Invitrogen). Transfected
cells were treated with E2, ICI 182780 (Faslodex) and
EtOH for 24 h, and lysates were harvested for luciferase
assays. The experiment was performed according to pro-
tocols from the manufacturer (Promega). Luciferase ac-
tivity was measured on a MLX Microtiter Plate Lumin-
ometer (Dynex Technologies, Chantilly, VA, USA).
Transient transfection and subcellular
localization of ERa
Using 24-well plates, UMR-106 cells were transiently
transfected using Lipofectamine 2000 (Invitrogen), with
full-length wildtype ERa inserted into the appropriate
ECFP vector (Clontech), along with red ﬂuorescent pro-
tein (pDs 1Red-N1; Clontech, Palo Alto, CA, USA) tar-
geted to the nucleus (nRFP). These two constructs were
detailed previously.
(32) Transfected cells were cultured for
24 h. Subsequently, cells were serum-starved by culturing
in the presence of 2% BSA for 4 h and treated with vehicle,
50 mM EtOH, 10
29 M E2, and 10
27 M ICI 182780 for 2 h.
The cells showing either nuclear or cytoplasmic accumu-
lation of ERa were directly visualized using a ﬂuorescence
microscopy with connection to a camera.
Senescence-associated b-galactosidase activity
and staining
Fully differentiated rat bone marrow stromal osteoblasts
in 6- and 24-well plates were treated with E2 for 30 min
before adding 50 mM EtOH, and plates were well sealed
for 24 and 48 h. The senescence-associated b-galactosidase
activity assay, performed using the b-galactosidase enzyme
assay kit (Promega), measured the absorbance at 420 nm
according to the manufacturer’s instruction. Cell b-galac-
tosidasestaining wasalso performed according to a method
published previously.
(34) Senescent cells were identiﬁed as
blue-stained cells by standard light microscopy.
Statistical analyses
Data are expressed as means ± SD. One-way and two-
way ANOVA followed by Student-Newman-Keuls post-
hoc analysis was used to compare the treatment groups.
Values were considered statistically signiﬁcant at p < 0.05.
TABLE 1. REAL-TIME RT-PCR PRIMER SEQUENCES
Gene Forward primer Reverse primer
ERa TCTGACAATCGACGCCAGAAT ACAGCACAGTAGCGAGTCTCCTT
ERb TGTGCCAGCCCTGTTACTAGTC CATGACCAAACGCCGTAATG
PTHLH GACAAGGGCAAGTCCATCCA GACACCTCCGAGGTAGCTCTGA
BMP6 TGGATCATCGCACCCAAAG TGTACAATGGCGTGGTTGGT
PDE3B GATTCTCTGGGACTGGGACTTG TGCGAGCTTCATTTAGCACTGA
BTF ACCAATTATCGAATGCCTGACA GAGCAGTCATCAACGACCAGAA
Autotaxin TCGTAGGTTATGGCCCAACTTT GGGCTTCAAGCCTAGGAGATC
STAG2 TGCAGAAAAGGTGACCAATTTG TGACGCAATAAGGCATCCAA
18S CCTGTAATTGGAATGAGTCCACTTT ATACGCTATTGGAGCTGGAATTACC
GAPDH TGAGGTGACCGCATCTTCTTG TGGTAACCAGGCGTCCGATA
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EtOH stimulates estrogen receptor overexpression
and activation of p53 and p21 in bone tissue
Using pQCT, we found that, in the EtOH-infused group,
trabecular BMD was signiﬁcantly lower compared with the
control total enteral nutrition group (control: 234.6 ± 11
versus EtOH: 182.7 ± 8.2 mg/cm
3, n =7 ;p < 0.05). E2
treatment (E2: 300.0 ± 11.2 mg/cm
3, n = 7) increased tra-
becular BMD (p < 0.05 versus control) and reversed the
effectofEtOHontibialtrabecularBMD(E2+EtOH:284.8
± 8.3 mg/cm
3, n =7 ;p < 0.05 versus EtOH). These results
were similar to those we have previously published.
(1) Using
RNA extracted from tibial bone, real-time PCR was carried
out for estrogen receptor subtypes a and b (ERa,E R b).
EtOH and E2 treatment both upregulated ERa and ERb
gene expression (p < 0.05), although EtOH had a larger
effect (Fig. 1A). Interestingly, in the E2 + EtOH group, E2
attenuated EtOH effects on both ERa and ERb gene ex-
pression. Similarly, this EtOH and E2 interaction was ob-
served when ERa protein levels were evaluated using
Westernblot (Fig. 1B). Because previous evidence indicated
thatEtOHcan increase p53expressioninhearttissue,
(35)we
measured p53 and its phosphorylation status along with p21
levels. Both total and phosphorylated p53 were increased in
the EtOH group, and E2 attenuated these effects (Fig. 1B).
The p21 protein expression pattern in bone was similar to
thatofp53proteinexpression inthe EtOH,E2,andEtOH+
E2 groups (Fig. 1B).
E2 and EtOH regulate common, ERa-,
and ERb-speciﬁc mediated genes in bone
Prompted by the above data that EtOH upregulates
ERa and ERb gene expression in bone, we next studied
EtOH and E2 cross-talk through ERa and ERb. The fol-
lowing six genes were selected: PTHLH, BMP6, PDE3B,
BTF, Autotaxin, and STAG2. According to data published
by Stossi et al.,
(13) PTHLH and BMP6 are considered
FIG. 2. Interactions of EtOH and E2 on ERa- and ERb-medi-
ated speciﬁc gene expression in bone. Real-time PCR was carried
out for six different ERa and ERb regulated genes using RNA
isolated from tibial bone. mRNA expression was normalized to
control GAPDH gene expression, (n = 7/group). Bars represent
means ± SD for n = 8–10 animals/group. Means with different
letters differ signiﬁcantly (p < 0.05, a > b > c > d) as determined by
two-way ANOVA followed by Student-Newman-Keuls posthoc
analysis for multiple pairwise comparisons.
FIG. 1. EtOH induces estrogen receptor expression and activation of p53 and its downstream effector p21 in bone. Tibial bone RNA
and proteins (n = 7/group) were isolated. (A) Real-time PCR was performed for ERa and ERb gene expression, and the volumes were
normalized to GAPDH control gene expression. (B) Western blots of ERa, p21, phospho-p53, total p53, and GAPDH are depicted
for four samples from control and EtOH groups and three samples from E2 and E2 + EtOH groups. Numbers represent means ± SD of
the ratios of intensity of the bands of each target proteins over GAPDH protein for each treatment. Bars represent means ± SD for
n = 7 animals/group. Means with different letters differ signiﬁcantly from each other at p < 0.05, a > b > c > d as determined by two-
way ANOVA followed by Student-Newman-Keuls posthoc analysis for multiple pairwise comparisons.
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and BTF are mediated speciﬁcally through ERa, whereas
Autotaxin and STAG2 are mediated through ERb spe-
ciﬁcally. Using RNA extracted from tibial bone and
real-time PCR analysis, we found that EtOH and E2 alone
upregulated all six genes with no speciﬁcities for either
ERa or ERb. Interestingly, in the EtOH + E2 group, all
six gene expressions were lower (p < 0.05) compared with
EtOH or E2 alone, especially Autotaxin and STAG2,
which were lowered back to control level (Fig. 2).
E2 interacts with EtOH to regulate ERa and ERb
gene expression in in vitro osteoblastic cell cultures
To further conﬁrm the interaction of E2 and EtOH on
ERa and ERb gene expression speciﬁcally in osteoblasts,
we used stromal osteoblasts derived from bone marrow
cells, calvarial osteoblasts isolated from neonatal calvaria,
and the UMR-106 osteoblastic cell line. In the ﬁrst set of
experiments, mature stromal osteoblasts derived from bone
marrow were treated with EtOH using 50 and 100 mM, with
or without 30-min 10
29 M E2 pretreatment. Twenty-four
hours later, RNA was extracted, and real-time PCR and
ERa andERb geneexpressionwerestudied.EtOHinduced
ERa and ERb gene expressions in a concentration-depen-
dent fashion. In agreement with the data we obtained in
vivo, E2 induced both ERa and ERb gene overexpression.
As we expected, E2 did not show an additive effect but
rather attenuated EtOH’s effect on both ERa and ERb
geneexpression at two different EtOHconcentrations (Figs.
3A and 3B). Similarly, in the second set of experiments,
concentration-dependent responses of ER gene expression
to EtOH were observed using isolated neonatal calvarial
osteoblasts, and E2 was also able to attenuate 50 mM
EtOH-induced expression of both ER genes (Figs. 3C and
3D). To test the hypothesis that the action of EtOH on ER
gene expression is non–receptor speciﬁc, we used ERa
speciﬁc agonists PPT and ERb speciﬁc agonist DPN to treat
UMR-106 osteoblastic cells with or without EtOH. We
found that PPT and DPN were able to attenuate EtOH-
induced ERa and ERb gene expression speciﬁcally (Figs.
3E and 3F). This suggested that EtOH stimulates ER gene
expression in a nonselective fashion but that ERa-a n d
ERb-speciﬁc pathways are involved in feedback regulation
of each receptor type. To test the hypothesis that EtOH
activates some common ER-regulated genes because of
activated oxidative stress in osteoblasts, we used UMR-106
osteoblastic cells and treated the cells with N-acetyl cysteine
(NAC), which is a well-known antioxidant chemical to-
gether with EtOH. We found that pretreatment with 10 mM
NAC not only attenuated EtOH-induced ERa and ERb
gene expression but also completely blocked EtOH-acti-
vated ER-regulated (common, ERa speciﬁc and ERb spe-
ciﬁc) gene expression in those osteoblasts (Figs. 3G–3K).
Differential effects of EtOH and E2 on ERE and p21
promoter reporter in UMR-106 osteoblastic cells
Based on the above observations that ER genes and p21
expression are induced by EtOH, we next compared the
FIG. 3. EtOH upregulates estrogen receptors and interacts with their ligands in vitro. Osteoblasts from three different sources were
used for identifying the action of EtOH on estrogen receptor gene expression and characterization of interactions with estrogen receptor
ligands. (A and B) Stromal osteoblastic cells cultured from control rat bone marrow cells were treated with EtOH at 50 and 100 mM
in the presence or absence of 10
29 M E2 (30-min pretreatment) for 24 h. (C and D) Isolated neonatal calvarial osteoblasts were treated
with EtOH at 50, 100, and 150 mM. 50 mM EtOH-treated wells were in the presence or absence of 10
29 M E2 (30-min pretreatment). (E
and F) UMR-106 osteoblastic cells were treated with 50 mM EtOH in the presence or absence of 10
28 ME R a-speciﬁc agonist PPT or
ERb-speciﬁc agonist DPN (30-min pretreatment) for 24 h. RNA was isolated,and ERa and ERb mRNA was measured by real-time RT-
PCR. All mRNA expressions were normalized to GAPDH mRNA expression. (G–K) UMR-106 osteoblastic cells were pretreated with
10 mM NAC for 30 min before adding 50 mM EtOH. After 24-h treatment, cell RNA was extracted. Real-time PCR was performed
for evaluation of indicated gene expression. Bars represent means ± SD. *p < 0.05 vs. control vehicle-treated cells.
#p < 0.05 EtOH vs.
E2 + EtOH in A and B, EtOH vs. PPT + EtOH in E, and EtOH vs. DPN + EtOH in F in 6-well plate triplicates as determined by two-
way ANOVA followed by Student-Newman-Keuls posthoc analysis for multiple pairwise comparisons.
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reporter and the p21 promoter. ERE-TK-Luc or the hu-
man pGL2-p21-Luc was transfected into UMR-106 osteo-
blastic cells, with or without co-transfection with ERa.
Transfected cells were treated with EtOH, E2, and ICI
and their combinations for 24 h. The cells were harvested
and assayed for luciferase activity. ERE-TK-Luc activities
were increased by up to 50% and 20% in response to
E2 with or without ERa, respectively. Interestingly, similar
to ICI, EtOH decreased ERE-TK-Luc activity by 40% in
the presence of ERa. However, EtOH had no effect
without exogenous ERa (Figs. 4A and 4B). In the absence
of exogenous ERa, the combination of E2 and EtOH in-
creased ERE-TK-Luc activity similar to that of E2 alone.
In the presence of exogenous ERa, the combination of
EtOH and E2 returned ERE-TK-Luc activity back to
control levels. In the combination EtOH and ICI treat-
ment, ERE-TK-Luc activity was decreased even further
compared with EtOH alone (Figs. 4A and 4B). EtOH had
an opposite effect on pGL2-p21-Luc activity compared
with its effect on ERE-TK-Luc activity. Whether exoge-
nous ERa was present or not, EtOH activated pGL2-
p21-Luc activity (Figs. 4C and 4D). E2 not only decreased
p21 luciferase activity on its own, but also attenuated
EtOH-induced activity in the absence of exogenous ERa
(Figs. 4C and 4D). On the other hand, ICI had no effect
on p21 luciferase activity by itself, and it had no effect
on EtOH-induced activity in the absence of exogenous
ERa. In the presence of ERa, both E2 and ICI slightly
activated pGL2-p21-Luc activity, and they both lowered
EtOH’s activation of pGL2-p21-Luc when combined with
EtOH, with E2 having a greater effect than ICI (Figs. 4C
and 4D).
FIG. 4. E2, but not ICI, alters EtOH-induced regulation of ERE-
TK-Luc and p21 promoter activities in osteoblasts. (A and B) Rat
UMR-106 osteoblastic cells in 24-plate quadruplicates were
transfected with ERE-TK-Luc plasmid with or without co-trans-
fection of wildtype ERa. (C and D) Rat UMR-106 osteoblastic
cells in 24-plate quadruplicates were transfected with pGL2-p21-
Luc plasmid with or without co-trnasfection of wildtype ERa.
Twenty-four hours later after transfection, cells were treated with
EtOH 50 mM, E2 10
29 M, ICI 10
27 M, and a combination of E2 +
EtOH and E2 + ICI (with E2 10
29 M and ICI 10
27 M 30-min
pretreatment before adding EtOH) for an additional 24 h. Lucif-
erase activity was measured. All data were corrected for renilla
activity and relative to control treated with or without ERa, re-
spectively. *Signiﬁcantly greater and **signiﬁcantly lower than
control vehicle treated cells in 24-well plate quadruplicates at p <
0.05.
#Signiﬁcantly different when EtOH and E2 + EtOH were
compared at p < 0.05 as determinedby two-way ANOVAfollowed
by Student-Newman-Keuls posthoc analysis for multiple pairwise
comparisons.
FIG. 5. Cellular localization of ERa in UMR-106 cells. UMR-
106 osteoblastic cells were grown in a 24-well plate, transfected
with an ERa-ECFG expression plasmid (0.4 mg/well) together
with nRFP nuclear anchor protein (0.1 mg/well), and treated with
vehicle, 50 mM EtOH, 10
29 M E2, and 10
27 M ICI for 2 h before
viewing (320 lens) directly under a ﬂuorescent microscopy con-
nected with a camera. In EtOHand E2 combinationtreatment(E2
+ EtOH), E2 was added 30 min before EtOH treatment. In the
EtOH-,E2+EtOH–,andICI-treatedcells,ERa-ECFGwas found
throughout the cell, whereas in E2-treated cells, ERa-ECFG
translocated into the nucleus. Pictures were taken under ﬂuores-
cent microscopy (320) from representative areas from each
treatment well.
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Fig. 5 live 4/CCellular localization of ERa in UMR-106 cells
To explore the differences of the effects of EtOH and E2
on estrogen receptor in bone cells, we compared the cel-
lular distribution of ERa-ECFP expression plasmid to-
gether with Nuc-ERFP in UMR-106 osteoblastic cells by
ﬂuorescent microscopy. After ERa-ECFP was transfected
into a cell, ERa was distributed mainly in the cytoplasm of
control treated cells. The addition of E2 resulted in rapid
nuclear translocation of ERa, whereas ERa from cells
treated with EtOH or ICI remained in the cytoplasm (Fig.
5). Like ICI, we found that the majority of ERa-ECFP was
in the cytosol after addition of EtOH to E2-treated cells for
2 h (Fig. 5).
Senescence-associated b-galactosidase activity
is increased in EtOH-treated osteoblasts
Previous reports have strikingly shown that an activating
mutation of p53 causes early onset of aging-associated
phenotypes in mice.
(36) Our above data showed that EtOH
induces p53 and p21 in bone. This further prompted us to
examine senescence-associated b-galactosidase activity in
osteoblasts treated with EtOH and E2. Mature stromal
osteoblasts were exposed to EtOH and E2 for 24 and 48 h.
b-galactosidase activity was increased 50% in EtOH-trea-
ted cells after 24 h and >100% after 48 h (Figs. 6A and 6B).
E2 completely blocked the effect of EtOH after 24 h but
only attenuated the effect after 48-h treatment. Consis-
tently, EtOH-treated cells showed more b-galactosidase
positive blue cells after 48 h (Figs. 6C–6F). Cell lysates
were collected after 24- and 48-h treatment for Western
blot analysis of ERa, p53, and p21 protein expression.
Similarly to what we found in bone tissue in vivo (Fig. 1B),
EtOH activated p53 and p21, whereas E2 attenuated these
effects (Figs. 6G and 6H).
DISCUSSION
In human alcoholics and in experimental animal studies,
EtOH has been shown to cause a variety of tissue damage.
For example, EtOH-induced liver damage resulting from
overproduction of reactive oxygen species (ROS) has been
well documented.
(37) We have previously developed a fe-
male rat model in which EtOH is infused overnight as part
of a system of TEN to mimic consumption patterns and
blood EtOH concentrations observed in alcoholics.
(1,2)
Using this model, we showed that bone loss occurred after
chronic EtOH infusion independent of nutritional sta-
tus.
(1,2) In addition, we showed that EtOH treatment re-
duces estradiol in cycling females and disrupts estrogen or
ER signaling in bone.
(1,6) In this report for the ﬁrst time, we
showed that EtOH also directly stimulates overexpression
of ERs in bone in vivo and in osteoblasts in vitro and that
this can be reversed by ER agonist treatment. In general,
ERs are ligand-inducible transcription factors. When
FIG. 6. EtOH induces ERa, activates p53 and p21, and increases senescence-associated b-galactosidase activities in bone marrow
stromal osteoblasts. Mature stromal osteoblasts derived from bone marrow cells in the presence of osteogenic medium were treated with
EtOH, E2, and E2 + EtOH for 24 and 48 h. (A and B) Senescence-associated b-galactosidase enzyme activity measured from cell lysates
collected 24 and 48 h after treatment. EtOH increased enzyme activity at 24 and 48 h; however, E2 blocked or attenuated the effects of
EtOH at either 24 or 48 h. (C–F) Senescence-associated b-galactosidase cell staining was performed after 48-h treatment. Blue stained
cells showed positive for senescence-associated b-galactosidase activity. (G and H) Western blots showed increased ERa, p53, and p21
and increased phosphorylation of p53 by EtOH in cell lysates collected at 24 and 48 h. E2, however, attenuated the effects of EtOH. The
numbers represent the ratio of intensity of the band of targeted protein over control GAPDH for a single treatment. Bars represent
means ± SD. *p < 0.05 vs. control vehicle treated cells in 6-well plate triplicates.
#Signiﬁcantly different EtOH vs. E2 + EtOH (p < 0.05
as determined by two-way ANOVA followed by Student-Newman-Keuls posthoc analysis for multiple pairwise comparisons).
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Fig. 6 live 4/Cbound to E2, ERs activate the expression of genes that
have estrogen responsive elements (EREs) in their pro-
moter regions. EtOH, which is not a ligand of ER, stimu-
lated both receptors to be overexpressed but also pre-
vented E2-stimulated ERa translocation to the nucleus
and downregulated ERE-luc reporter activity in osteo-
blasts. These data suggest that the ability of EtOH to up-
regulate ER expression is a feedback consequence of im-
paired ER signaling. In agreement with our present data, a
previous study reported that ER concentration is increased
in hepatocytes after EtOH stimulation and suggested that
EtOH administration could be considered as a form of
chemical castration.
(38) However, these data are in contrast
to previously published data in human breast cancer cell
lines in which EtOH and E2 synergistically activated ERE-
luc reporter activity.
(15) This may suggest tissue-speciﬁc
interactions between EtOH and ER signaling.
Bone tissue is known to express both ERs, unlike other
tissues such as uterus, liver, ovary, and prostate, where one
of the two ERs predominates.
(39) We attempted to ﬁnd
differences between ERa- and ERb-regulated gene ex-
pression in osteoblasts in response to EtOH stimulation.
By far, the most extensive previous evidence on ER-spe-
ciﬁc signaling in osteoblasts has been recently published
by Stossi et al.
(13) They showed that, in human osteoblastic
cells, BMP6 and PTHLH are ERa and ERb common,
PDE3B and BTF are ERa speciﬁc, and ENPP2 and
STAG2 are ERb-speciﬁc genes in response to E2.
(13) We
found that E2 induced expression of all of these genes but
that the combination of E2 and EtOH attenuated this re-
sponse. These data are also consistent with the hypothesis
that EtOH impairs ER-mediated signaling in osteoblasts.
An interesting ﬁnding in this study was that the p21
promoter in osteoblasts is activated by EtOH in the pres-
ence or absence of exogenous ERa and that p21 protein
expression was signiﬁcantly increased. This was accompa-
nied by increased phosphorylation of p53. The biological
signiﬁcance of these ﬁndings is that p53 and p21 have
previously been found to be accumulated in alcoholic tis-
sues and associated with cancer occurrence.
(40) In normal
physiologic situations, in breast cancer cells, ER and p53
exert opposing effects on cellular proliferation. Recent
evidence has shown that ER may directly bind to p53,
leading to downregulation of transcriptional activation by
p53.
(41) There is a lack of extensive evidence on the rela-
tionship between ER and p53 in osteoblasts and how es-
trogen regulates p53 is also controversial.
(42) b-galacto-
sidase is well established as a biomarker to identify
senescent cells in culture and aging skin in vivo.
(34) The
increase in p21 expression and p53 activity after EtOH
treatment was associated with higher levels of SA-b-
galactosidase activity. This suggests that the senescence
pathway is activated by EtOH in these osteoblasts. Our
data showed that co-treatment of EtOH-treated osteo-
blasts with E2 resulted in a reversal of effects on p21 pro-
moter activation, p21 overexpression, and p53 phospho-
rylation and inhibition of EtOH-induced senescence.
These data are consistent with our previous studies that
have shown that E2 treatment can prevent EtOH-induced
bone loss in female rats
(1,6) and suggest negative cross-talk
between ER-mediated signaling and EtOH-stimulated cell
signaling.
In this regard, the one surprising ﬁnding of this study was
that the six ER-regulated genes we chose to study—BMP6,
PTHLH, PDE3B, BTF, ENPP2, and STAG2—were all
expressed at higher levels after EtOH treatment alone in
addition to being induced by E2 but that the combination
of EtOH and E2 led to reduced expression. The most likely
explanation for this apparently contradictory ﬁnding is that
EtOH induces these genes through an ER-independent
pathway probably involving increased production of ROS
in osteoblasts
(6) and that negative cross-talk of E2 on
EtOH signaling and of EtOH on ER signaling explains the
effects of EtOH + E2 (Fig. 7). Another less likely possi-
bility is that, although EtOH inhibits ER-mediated sig-
naling through ERE elements, it could stimulate some ER-
mediated signaling pathways through indirect effects on
ER interactions with transcription factors at other ele-
ments such as AP1 or Sp1 sites.
(43–45) In this regard, it
should be pointed out that, as with p21 in this study, in our
previous studies with RANKL in osteoblasts, E2 treatment
either has no effect or suppresses RANKL mRNA, EtOH
induces RANKL mRNA expression, and the combination
of E2 and EtOH prevents this induction.
(1,6) In addition,
osteoblasts treated with the antioxidant NAC together
FIG. 7. Working hypothesis describing interactions between
EtOH and E2 in osteoblasts. Estrogens act on osteoblast through
their receptors (ERs) and ER is translocated into the nucleus
where it activates estrogen responsive elements (ERE), leading
to altered gene expression promoting osteoblast survival. On the
other hand, EtOH diffuses cells where it is metabolized to acet-
aldehyde (Acet) by alcohol dehydrogenase class I (ADH1) and
also gives rise to reactive oxygen species (ROS), which can exert
several biological effects on the cell: (1) it may activatethe p53/p21
complex,(2) it may activateAREs, which have notbeen identiﬁed,
and/or (3) it may also block the ER nuclear translocation. These
observations suggest the existence of EtOH and E2 cross-talk in
osteoblasts that can alter cell fate.
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induced gene expression. These observations further sug-
gested that ROS is involved in the negative cross-talk of E2
on EtOH signaling in osteoblasts. However, whether the
putative ER membrane (versus nuclear) pathway is re-
sponsible for this effect clearly needs to be investigated in
future studies. Moreover, G protein–coupled receptors,
which have currently been shown to directly bind estro-
gen,
(46) may be the other possible mechanism for the effect
of EtOH in osteoblasts.
From our data, as summarized in Fig. 7, we believe that
EtOH-triggered accelerated osteoblastic cell senescence
results from activation of p53 and p21. This action of EtOH
and negative cross-talk between EtOH signaling and ER-
mediated pathways contributes to osteoporotic bone loss in
chronic alcohol drinkers and protective effects of estrogens
on EtOH-induced bone loss.
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